{"acquisitions":[],"changes":[],"country":"GB","description":"Verdiva Bio is a UK clinical-stage biotech advancing oral GLP-1 and incretin-based therapies for obesity and cardiometabolic disease. Patients with obesity are the eventual target population. The lead program VRB-101 is in Phase 2 trials as a once-weekly oral peptide.","domain":"verdiviabio.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":51.515066,"lng":-0.142502,"location":"London","multiples":[],"name":"Verdiva Bio (alt)","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":411000000,"connectionsAmong":[],"currency":"USD","date":"2025-01-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"verdiviabio-com-2025-01-01-series-a","source":{"fact":"round","publisher":"sifted","retrievedAt":"2026-04-30","status":"attributed","url":null},"status":"attributed","type":"series-a","url":null}],"slug":"verdiviabio-com","sources":[{"fact":"round","publisher":"sifted","retrievedAt":"2026-04-30","status":"attributed","url":null},{"fact":"existence","publisher":"verdiviabio.com","retrievedAt":"2026-04-30","status":"self-reported","url":"https://verdiviabio.com"},{"fact":"description","publisher":"verdiviabio.com","retrievedAt":"2026-04-30","status":"self-reported","url":"https://verdiviabio.com"}],"stage":"series-a","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":411000000,"traction":[],"updatedAt":"2026-04-30","valuations":[]}